Life Sciences Archive » May, 2014

Life Sciences - May, 2014

339 articles

• Humana Hits Medtronic With RICO Suit Over Infuse Claims
• Pfizer To Pay $325M To End Neurontin Off-Label Suit
• PhRMA Cries Foul On FDA Drug Labeling Guidance
• Will The Bidder-Activist Model To Buy Allergan Catch On?
• 6 Ways To Be A Go-To Firm For FCA Whistleblowers
• FTC Clears Forest Labs' $1.46B Furiex Buy
• AstraZeneca, McKesson Hid Crestor's Diabetes Link, Suit Says
• AstraZeneca Seeks To Block Actavis' Generic Diabetes Drug
• Taxation With Representation: Tax Counsel On The Deal
• Teva Retains Inside Track To Market Generic Celebrex
• Valeant Again Boosts Allergan Bid, This Time To $53B
• 5 Legal Headaches Casinos Face From Medical Marijuana
• Warner Chilcott Settles Suit Over $8.5B Actavis Deal
• J&J Unit Gets Ex-Employee Barred From Selling Devices
• Female Powerbrokers Q&A: Michael Best's Mary Turke
• Female Powerbrokers Q&A: Husch Blackwell's Hayley Hanson
• Can Bankrupt Law Firms Claw Back 'Unfinished Biz' Profits?
• NY Judge Won't Toss FCA Kickback Suit Against Novartis
• Kaneka's Suit After Adverse Claim Ruling Doesn't Merit Fees
• Italy Seeks €1.2B From Roche, Novartis On Antitrust Claim
• Biotech Co. Hit With Class Action Over Alzheimer's Product
• FDA Overhauls Guidance On Speedier Drug Approvals
• Deals Rumor Mill: GSK, Softbank, Swift Worldwide
• Indirect Skelaxin Purchasers Strike $2M Deal With Mutual
• China Fines J&J, Other Lens Makers $3M In Antitrust Probe
• Ex-ArthroCare Execs Can't Duck $400M Fraud Charges
• Cooley Adds Ex-Fish & Richardson IP Partner In Boston
• Forest Labs Settles Investor Suits Over $25B Actavis Deal
• Advice From Counsel: The Emerging E-Discovery Playbook
• Ophthalmic Drugs And What They Say About EU Antitrust
• Female Powerbrokers Q&A: Whyte Hirschboeck's Gina Carter
• Female Powerbrokers Q&A: Stewart Bernstiel's Bernstiel
• Is It Time To Increase Your Billing Rates?
• Obvious-To-Try Lessons From 2 Fed. Circ. Rulings
• High-Stakes Litigators Can Cost $1,500 An Hour
• GCs Question If Partners Are Worth The Cost
• BigLaw Hourly Rates Dwarf Rivals' Across The Board
• JPML Asked To Combine Suits Over Bayer's Mirena In Tenn.
• Engineer Admits To Stealing Secrets From Becton, Bard
• 340B Reforms In Doubt After Judge Curbs HHS Power
• Medtronic To Pay US $10M To Settle Whistleblower FCA Suit
• 5 Insights From Ingram Micro's Lily Hughes
• Vivus Investor Unveils Plans For $640M Buyout Offer
• Hikma Pharma Offers Up To $300M For Injectables Biz
• Edwards Wildman Snags IP Pro From Thompson Coburn
• FDA Finalizes Adulterated Drug Seizure Rule
• Judge Sends Abuse-Resistant OxyContin Patents To Trial
• Boehringer Pays $650M To Settle Pradaxa MDL
• GNC Evades False Ad Action Over Amino Acid Supplements
• Female Powerbrokers Q&A: Kilpatrick's Mehrnaz Boroumand
• Valeant, Ackman Unveil Sweetened $50B Allergan Bid
• Nestle Spends $1.4B On Valeant Skin Care Rights
• A Wake-Up Call For Cos. With Corporate Integrity Agreements
• 5th Circ. Hands Win To Novartis In Bone Drug Action
• Nordion Delays Shareholder Vote On $758M Sterigenics Deal
• Fed. Circ. Won't Invalidate Hearing Aid Patent Claims
• GSK Faces Investigation By UK's Serious Fraud Office
• Pharmacia, Solutia Seek Help For Superfund Cleanup In Suit
• China Asks US To Back Vitamin C Antitrust Appeal In 2nd Circ.
• And Now A Word From The Panel: What's Good For America?
• Pharma Group Beats Orphan Drug Discount Rule In 340B Fight
• J&J Hit With Class Action Over Listerine False Labels
• Athena Seeks High Court Review Of Eyelash Competition Claim
• Pfizer's Megadeal Collapse Won't Hurt Red-Hot Pharma M&A
• Allergan Rips Valeant's Biz Model As Heftier Bid Looms
• FDA's Biosimilar Rules Will Provide Testing Clarity
• Hyman Phelps Rips FDA Over Ranbaxy Exclusivity
• High Court Declines $42M Fen-Phen Fund Atty Looting Case
• Female Powerbrokers Q&A: Barnes & Thornburg's McGee
• Otsuka Sues Aurobindo To Halt Generic Abilify
• 5 Insights From MetLife General Counsel Ricardo Anzaldua
• Pfizer Drops $118 Billion AstraZeneca Bid As Time Runs Out
• Novel, Braintree Say Fed. Circ. Ruling Upends Hatch-Waxman
• Obama Administration Will Not Force New Cybersecurity Rules
• Judge Invalidates Prometheus' Patent For Irritable Bowel Drug
• J&J Urges Judge To Rule Philly Risperdal Cases Time-Barred
• Stryker Faces Barrage Of Suits Over Hip Implant Corrosion
• Watson Latest Target Of Amarin's Vascepa Patent Suits
• General Star Looks To Duck Coverage In Aging Drug Row
• Medtronic Gets Some Sanctions Cut In Morphine Death Suit
• 'Right To Try' Bills Raise New Hurdles For Drug Approvals
• J&J Unit's Patent Claim Survives Despite Fed. Circ. Ruling
• NJ Casino Guest's Suit Says Medical Pot OK Under State Law
• USPTO Rules Will Set Back Antibiotic Drug Development
• Pfizer Investor Suit Hits Roadblock As Expert Report Tossed
• Female Powerbrokers Q&A: Shearman's Antonia Stolper
• Female Powerbrokers Q&A: Keating Muething's Rachael Rowe
• Rader Resigns, Apologizes For Email To Weil Atty
• Female Workers Win Conditional Cert. In Daiichi Sex Bias Suit
• US Urges High Court Not To Pick Up Medtronic Pain Pump Row
• CMS Expands Prepayment Scrutiny For Medical Equipment
• Ariad Investors Decry Bid To Nix Failed Leukemia Drug Suit
• Calif. Counties Claim Pharma Cos. Lied About Opioid Safety
• FDA, Others Seize Drugs In Global Online Pharmacy Raids
• Nev. Jury Vindicates Takeda In Actos Injury Trial
• 5 Insights From Hewlett-Packard GC John Schultz
• Cephalon Dodges Off-Label Suit Over Union Benefits Costs
• From Sea To Shining Sea: French And US Sunshine Laws
• Ex-Pfizer Execs Can't Duck Class Action Over Celebrex Risks
• Pfizer's Hopes For Landmark Merger Dim As Deadline Nears
• Medical Cos. Escape FCA Kickback Suit Over Amgen Drug
• Female Powerbrokers Q&A: Cohen & Gresser's Bromberg
• Preemption Doesn't Bar $4M Topamax Win, Pa. Court Hears
• Browne George Faces Malpractice Suit Over Sargon-USC Row
• HHS Watchdog Updates Policies On Drug Charity Kickbacks
• Judge Tosses Reckitt's Suboxone Infringement Suit
• How An Antitrust Case Changed The Gay Marriage Debate
• McKesson Hit With Suit Over Celesio Shareholder Payout
• Food Fights Make A Mess In California District Courts
• The Trial Lawyer's Guide To A Winning Direct Examination
• Drugmakers, Insurers Battle Over Surging Big Pharma Prices
• 5 Insights From Caterpillar Chief Legal Officer Jim Buda
• Pa. Justices Will Hear $28M Zimmer Knee Injury Dispute
• Ackman Prods Allergan For Outside Review Of $46B Takeover
• Deals Rumor Mill: Alstom, PHH, Helios
• Committee Sends HHS Chief, Trade Nominees To Full Senate
• Female Powerbrokers Q&A: Blank Rome's Linsey Bozzelli
• Judge Won't Revive FCA Whistleblower Claims Against Bayer
• Deals Rumor Mill: Commerzbank, Repsol, Wencor
• Case Over Skelaxin 'Sham' IP Suits Heads To State Court
• FDA Warns Sun Pharma Over 'Pervasive' Data Deletions
• The No-Nonsense New Yorker: Justice Jeffrey K. Oing
• 5 Insights From Prudential General Counsel Susan Blount
• Medtronic Pays Edwards $750M To End Heart Valve IP Row
• FTC Wants Weight-Loss Marketers To Take A 'Gut Check'
• Wal-Mart, Walgreen Settle Cartilage Supplement Suits
• Female Powerbrokers Q&A: Troutman Sanders' Amie Colby
• Valeant Upgrade To $46B Allergan Bid Will Include Stock
• Major AstraZeneca Investor Urges $118B Pfizer Merger Talks
• NECC, Tenn. Reach $5M Deal Over Meningitis Outbreak
• Mylan Can't Use Generic Paxil Case Docs For New Suit
• China Says GSK Avoided $16M In Taxes, Duties
• Justices Won't Weigh In On USPTO's Verdict-Nixing Power
• Bankrupt Savient Wins Approval For Ch. 11 Plan
• Payment Policies Finalized For Medicare Advantage, Part D
• 5 Insights From Microsoft Deputy GC David Howard
• FDA Off-Label Limits Breach Free Speech, Legal Group Says
• Fed. Circ. Revives Dispute Over Spinal Nerve Injury Drug
• Roche To Invest $135M On New Basel Facilities
• Female Powerbrokers Q&A: Zelle's Judy Langevin
• Supplement Co.'s $2M Suit Says Marketer Stole Trade Secrets
• A Guide To USPTO Guidance On Patentable Subject Matter
• AstraZeneca Turns Down Pfizer's Sweetened $118B Bid
• Ackman Attacks Allergan CEO In Push For $46B Valeant Deal
• Herbal Testosterone Supplement Makers Face RICO Action
• GlaxoSmithKline Gets 115 Avandia Injury Cases Dismissed
• Brand Battles: Cosmopolitan, Major League Baseball, Novartis
• Fisher Scientific Scores $120M DOD Lab Supply Contract
• Mylan Curbs Medicines Co.'s Expert In Angiomax Patent Trial
• ViroPharma Can't Shake Shareholders' Class Action
• Boardroom Confidence, Shareholders Buoy Hostile M&A
• Abbott Drops $3B On CFR To Bulk Latin America Pharma Biz
• High Court Told Galderma Acne Gel Patent Claims Not Invalid
• ABA Opens Doors For Reviewing Jurors' Social Media
• Fed. Circ. Leaves UPenn Alzheimer's Patent Win Untouched
• SEC Warns Pot Investors Of Scams As GrowLife Execs Sued
• Female Powerbrokers Q&A: Frost Brown Todd's Beth Naylor
• Female Powerbrokers Q&A: Genova's Kathleen Einhorn
• Law Practice Is Evolving Via 'Legal Project Management'
• FDA Drops Lunesta Dose To Fight Morning Drowsiness
• FTC Brews False Ad Suit Over Pure Green Coffee Diet Claims
• Conor MedSystems Can't Escape $100M Contract Suit
• American Meat May Whet Supreme Court Appetite
• Diet Tea Maker Can't Escape Consumer Class Action
• GOP Senators Block Tax Extenders Bill, Demand Amendments
• 5 Insights From Aetna General Counsel William Casazza
• Takeda Avoids Another Big Loss In Ill. Actos Cancer Trial
• $106B Pfizer-AstraZeneca Offer Draws Global Scrutiny
• Biogen Gets Attys' Fees In Classen Immunization IP Row
• Generics Maker Wins Alimta Fight With Lilly In UK Court
• Wockhardt Recalls Blood Pressure Drug In US
• Merck Hit With Suit Over Mass Layoffs At Defunct Med Co.
• FDA Chides Alvogen Over Black Box Omission
• Female Powerbrokers Q&A: Lowenstein's Sharon Levine
• Bayer OKs $415M Sale Of Device Unit To Boston Scientific
• Judge Tosses Teva's 'Premature' Suit Over Generic Copaxone
• Novartis Prevails In Bone Drug Trial In NC
• Fed. Circ. Ruling Nixed J&J Unit's Patent Claim, Rival Says
• HHS Chief Nominee Breezes Through Second Senate Hearing
• Diet Drugs' Maker To Pay $40M, Issue Recall Over Labeling
• Drinker Biddle Sanctioned For Pelvic Mesh Suit Removal
• J&J, Bayer Rip FDA's Over-The-Counter Reforms
• Deals Rumor Mill: AstraZeneca, Carlyle, BWAY
• Eli Lilly Can't Escape Cialis Patent Infringement Suit
• 5 Insights From Cisco General Counsel Mark Chandler
• Cannabis Credit Co-Ops Won't Solve Pot Banking Dilemma
• Wash. City Won't Delay Licenses For Marijuana Sales
• Female Powerbrokers Q&A: Kilpatrick's Audra Dial
• Novartis Can't Shed Warning Claims In Aredia Jaw Death Suit
• Family Tree Shares DNA Test Results, Consumers Allege
• McKesson Cuts Offer Price To Finish $8.4B Celesio Takeover
• 5 Red Flags In Pharmaceutical Settlements
• FDA Sheds New Light On Biosimilars Approval Pathway
• Preemption Dooms Branded, Generic Reglan Suit In 5th Circ.
• Medtronic Can't Duck Negligence Claims Over Spinal Devices
• The Tenacious Technocrat: Judge Francis Allegra
• Teva's Bid To Block Generic MS Drug Is Premature, FDA Says
• J&J Units Hit Mylan With IP Suit Over Concerta Generic Bid
• Sanofi-Aventis Fails To Kill FCA Suit Over Lovenox
• Fed. Circ. Judge Denies Fees, Even After Octane Fitness
• 5 Insights From MassMutual General Counsel Mark Roellig
• Female Powerbrokers Q&A: Butler Snow's Christy Jones
• Merck To Get $600M For Eye-Care Biz in Japan, Europe
• Pfizer Could Raise Contested $106B AstraZeneca Merger Bid
• Valeant To 'Improve' Terms After Allergan Rejects $46B Bid
• Wal-Mart, Walgreen Want Supplement Suit Consolidated In NY
• Chelsea Therapeutics $658M Merger 'Unfair,' Investors Say
• Stryker Gets 8th Circ. Win In Pain Pump Injury Suit
• 5 Insights From UPS Chief Legal Officer Teri McClure
• Daiichi Sankyo Wants Hold On $3B Ranbaxy Sale Lifted
• Novartis Can't Beat Back NY Aredia-Zometa Suit
• 10th Circ. Denies Ceragenix Whistleblower's Arbitration Bid
• Muscle-Builder False Ad Suit's Figure Too Small, Judge Says
• Davis Polk Guides Shire In $260M Liver Drug Maker Buy
• Novartis Gets Punitive Damages Barred In Bone Drug Suit
• Device Firms Get New FDA Insights On Consensus Standards
• Valeant, Ackman Poised To Go Hard In $46B Allergan Fight
• GNC Rips Plaintiff Studies In Bid To Kill Supplement MDL
• Actavis Strikes Deal With Valeant Over Generic Acne Gel
• Holland & Knight Adds Life Sciences Pro To Miami Team
• Female Powerbrokers Q&A: Meyer Suozzi's Lois Schlissel
• Allergan Rejects $46B Hostile Bid From Valeant, Ackman
• Marijuana Products May Provoke Product Liability Suits
• Brazil Court Fines Eli Lilly $450M Over Heavy-Metal Poisoning
• Generics Cos. Denied Quick Appeal In AndroGel Row With FTC
• New USPTO Eligibility Rules Threaten Patent System, Attys Say
• Medtronic Hit With $15M Verdict Over Spine Device Deal
• Fed. Circ. Rejects Petition Alleging Vaccines Led To Autism
• Balancing The Cost Of Legal Research Investments
• Teva Seeks Ban On Generic MS Drug Approvals By FDA
• Endo Sued In Philly Over Fortesta Testosterone Gel
• Deals Rumor Mill: Allergan, Alstom, Seven Generations
• Backlash Over $106B Pfizer-AstraZeneca Deal Spans Atlantic
• Female Powerbrokers Q&A: Kasowitz's Linda Kornfeld
• Female Powerbrokers Q&A: Frandzel Robins' Pat Trendacosta
• Taxation With Representation: Tax Counsel On The Deal
• Kirkland Helps Akorn Clinch $440M Deal For Niche Drugmaker
• House Passes Bill To Make R&D Tax Credit Permanent
• Boston Scientific Discloses HHS Subpoena Over Defibrillators
• Bartlett Doesn't Bar Darvocet Defect Claims, 6th Circ. Told
• Door Open For Animal Clone Patents Despite Dolly Ruling
• Sun Pharma Recalls 428K Substandard Pill Bottles
• NJ Employer Group Bashes Watchdog Whistleblower Ruling
• POM V. Coke May Impact Many FDA-Regulated Products
• Denmark's Lundbeck To Pay $658M For Chelsea Therapeutics
• HHS Head Nominee Sails Through First Senate Hearing
• Coapt Cuts Coverage Deal For Defective Wrinkle Gel Suits
• Ex-Duane Morris Partner Named GC Of Pa. Med Device Co.
• FTC Says Noerr Doesn't Shield AndroGel Pay-For-Delay Deal
• 5 Insights From Sprint General Counsel Charlie Wunsch
• Female Powerbrokers Q&A: Brinks' Laura Beth Miller
• Valeant, Ackman Eye Allergan Board Shake-Up Amid $46B Bid
• Venable Lands Gibbons IP Litigator For NY Office
• Lowenstein Sandler Lands Forest Labs GC
• Rebuttal: Mandatory Pro Bono Is Needed
• Medtronic Due $33M For Leaky Spine Device, Jury Told
• Glaser Weil Can Go After USC-Sargon Atty Fees Award
• Obama Threatens R&D Tax Credit Veto Before House Vote
• St. Jude Medical Says DOJ Probing Potential FCA Violations
• AIG Unit Tries To Upend $3.75M Ad-Injury Verdict
• J&J Unit Gets Punitives Barred In Pa. Risperdal Cases
• Ropes & Gray Leads Kohlberg In $800M Phillips-Medisize Sale
• Boston Scientific Drops $65M For IoGyn, Uterine Surgery
• Meda Eyes Its Own Deals After Spurning $24B Mylan Tie-Up
• BakerHostetler Bolsters IP Practice With Ballard Spahr Atty
• Female Powerbrokers Q&A: Munsch Hardt's Deborah Perry
• 5 Insights From News Corp. GC Gerson Zweifach
• 3rd Circ. Says Cigna Coverage Row Shouldn't Be Arbitrated
• Sanofi Gets Nod For 3rd Circ. Junk Fax Appeal
• Compounder Reaches $100M Deal In Meningitis Outbreak MDL
• J&J Unit Faces 1st Morcellator Suit Since FDA Warning
• FTC Denied Bid To Add Teva To Cephalon Pay-For-Delay Suit
• Medtronic To Pay $22M To Resolve Some Bone Graft Suits
• 3 Straw Men On A Witch Hunt Over Novartis Drugs Suit
• Nev. Gambling Licensees Get Medical Marijuana Warning
• Roxane Seeks To Nix 'Improperly Issued' AbbVie HIV Patent
• FDA Floats Labeling Update For 100s Of Drugs
• Arent Fox Adds 5 Hewitt Wolensky & McNulty Attorneys In LA
• Elder Statesman Of The Capital Court: Judge Paul Friedman
• FDA To Scrutinize Pharma Ad Pricing Claims
• Walgreens Can't Shake Cartilage Supplement False Ad Suit
• FTC Promotes Staff Attys On Google, Actavis Cases
• Bayer To Pay $14B For Merck Consumer Products Unit
• Janssen Can't Shake $11M Verdict In Topamax Case
• An Innovative Model For Collaborative Pro Bono
• AstraZeneca Lays Out Growth Plan In Wake Of $106B Pfizer Bid
• Female Powerbrokers Q&A: Blank Rome's Carol Joseph
• Double-Patenting Ruling Creates Pitfalls For Applicants
• 5 Insights From Archer Daniels Midland GC Cameron Findlay
• Think Like A Screenwriter: 5 Tips For Trial Lawyers
• Aspirin Doesn't Prevent First-Time Heart Attacks, FDA Says
• Fed. Circ. Snuffs U of Ill. Bid To Stop Inter Partes Review
• Fla. Medical Marijuana Approval Prompts Akerman Task Force
• Deals Rumor Mill: Energy Future, Pfizer, Siemens
• Hospitals Harmed By FDA Glucose Meter Standards, AHA Says
• IRS Says Savient's Ch. 11 Plan Is Missing Tax Payments
• Peregrine Again Escapes Investor Suit Over Lung Cancer Drug
• Lupin Blasts FDA's Call On Celebrex Generic Exclusivity
• Elan Pharma Dinged $3M In NJ Back Taxes
• Smoke 'Em If You Got 'Em: E-Cigarette Regs Heating Up
• 3rd Circ. Won't Rehear Controversial Bayer False Ad Ruling
• 5 Insights From AIG General Counsel Tom Russo
• FDA Med Device Enforcement Data Shows Rise In Violations
• Female Powerbrokers Q&A: Bracewell's Dee Martin
• Nordion Board OKs Sterigenics' Upped $758M Buyout Offer
• Fla. Medical Marijuana Bill Heads To Governor's Desk
• Solomon Seeks $3.8M From Spirogen For AstraZeneca Deal
• Allergan Hits Aurobindo With IP Suit Over Pinkeye Drug
• Whistleblower Says Medical Device Co. Defrauded Stryker
• FDA Rejects Petitions Over Lost Drug Exclusivity
• Brand Battles: Pabst Blue Ribbon, Booking.com, Diageo
• FCA Wave Sparks Debate Over DOJ Power To Boot Weak Suits
• Deals Rumor Mill: GE, Merck, York Risk
• State AGs Urge 3rd Circ. To Reverse Pay-For-Delay Ruling
• Circuit Splits Surrounding FCA Endure Post-Takeda
• Cryolab Hosting Ted Williams' Remains Loses Defamation Suit
• Amarin Targets Dr. Reddy's Over Vascepa Generic
• Warner Chilcott Rips Mylan Bid For Quick Win In Doryx Case
• Female Powerbrokers Q&A: Fine Kaplan's Bobbi Liebenberg
• Female Powerbrokers Q&A: Hiscock's Connie Cahill
• AstraZeneca Snubs Pfizer's Sweetened $106B Offer
• Cardiosom's Medical Contract Suit Survives US Challenge
• Medical Marijuana Bill Clears Fla. House
• Medical Device Co. Can't Shake Faulty Implant Claims
• Celgene, Astellas Hit Fresenius With Lymphoma Drug IP Suit
• Calif. Supreme Court Takes Up Medtronic Injury Row
• Avanir Prevails Over Par, Impax In Nuedexta Patent Row
• FTC Urges Advertisers To Police False Weight-Loss Claims
• Actavis Seeks En Banc Review Of Fed. Circ. Endo IP Ruling
• Wyeth Claims Immunity Against Effexor Pay-For-Delay Suit
• Norton Rose, Snell Attys Hit With Sanctions In Actos Case
• Deals Rumor Mill: Pfizer, Sprint, AT&T
• Ex-Rep Says Forest Labs Pushed Off-Label Use Of Namenda
• Pfizer Says It Doesn't Belong In Testosterone Gel MDL
• Best In-House Practices To Mitigate Cross-Border Risks
• Colo. Gov. Set To Sign Advanced-Industry Tax Break Bills
• Huge Pharma Deal Prospects Prop Up M&A Again In April
• Female Powerbrokers Q&A: McManis' Sharon Kirsch
• Female Powerbrokers Q&A: BatesCarey's Maria Enriquez